Stronger and Sustained Biomarker Response

The randomized, double-blind study compared efdoralprin alfa with conventional plasma-derived augmentation therapy in adults with AATD-associated emphysema. Patients receiving efdoralprin alfa every three weeks demonstrated markedly higher increases in functional alpha-1 antitrypsin (fAAT) trough levels—more than threefold greater than those observed with weekly standard treatment. The primary endpoint was met with high statistical significance.

Importantly, individuals treated with efdoralprin alfa maintained fAAT concentrations above the threshold considered protective for the entire 32-week study period. In contrast, this level was sustained for less than half of the time among patients receiving standard therapy. All secondary endpoints were also achieved, reinforcing the consistency of the benefit.

Addressing an Unmet Clinical Need

AATD is a genetic disorder marked by insufficient levels of alpha-1 antitrypsin, a protein that protects lung tissue from inflammatory damage. Without adequate levels, patients are vulnerable to progressive lung deterioration, frequently developing emphysema—a leading contributor to mortality in this population.

Despite its clinical consequences, AATD remains significantly underdiagnosed, with the majority of affected individuals unaware of their condition. Current augmentation therapies, introduced decades ago, require frequent infusions and do not consistently maintain protective protein levels.

Investigators noted that the pharmacologic design of efdoralprin alfa—a recombinant AAT-Fc fusion protein with extended half-life—may allow for more durable restoration of normal protein concentrations, reducing treatment burden while improving disease control.

Safety and Tolerability

Efdoralprin alfa was generally well tolerated, with a safety profile comparable to existing therapy. No treatment-related adverse events led to discontinuation. The most frequently reported events included COPD exacerbations, headache, and COVID-19 infections.

Notably, moderate or more severe COPD exacerbations occurred less often in the every-three-week dosing group compared with both the every-four-week regimen and standard therapy. Anti-drug antibodies were detected in a small number of patients but were transient and did not impact treatment activity.

Study Design and Next Steps

The ElevAATe trial enrolled 97 participants, randomized to receive efdoralprin alfa every three or four weeks or weekly plasma-derived therapy. The results, presented at the 2026 American Thoracic Society International Conference, support continued clinical development.

The therapy has already received both fast track and orphan drug designations in the United States, as well as orphan designation in the European Union. Ongoing extension studies are evaluating long-term outcomes.

Potential Impact

If confirmed in later-stage trials, efdoralprin alfa could become the first therapy to consistently normalize AAT levels with less frequent dosing. Experts suggest this approach could shift the treatment paradigm for AATD, a field that has seen limited innovation for decades.

While additional data are needed before regulatory approval, the findings highlight the promise of a restorative strategy aimed at correcting the underlying protein deficiency rather than simply supplementing it intermittently.